T 1612/16 (Anti-Futrin 2 antibodies/ONCOMED PHARMACEUTICALS) of 21.06.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T161216.20220621
- Date of decision
- 21 June 2022
- Case number
- T 1612/16
- Petition for review of
- -
- Application number
- 09170230.8
- IPC class
- C12Q 1/68
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (R-Spondins)
- Applicant name
- Deutsches Krebsforschungszentrum
- Opponent name
- OncoMed Pharmaceuticals, Inc.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention Art 83
- Keywords
- Main and auxiliary requests I to VI - subject-matter extends beyond content of earlier application (yes)
Inventive step - auxiliary request VII (yes)
Sufficiency of disclosure - auxiliary request VII (yes) - Catchword
- -
- Cited cases
- T 0609/02
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form with the following claims and a description and drawings to be adapted thereto:
claims 1 to 6 of auxiliary request VII filed with the reply to the statement of grounds of appeal.